Biotech firm Pulmatrix Q3 loss widens with clinical programs paused
Overview
US biopharma reported Q3 net loss per share of $0.34 as clinical development remains on hold
General and administrative expenses rose due to merger-related activities
Company expects Eos SENOLYTIX merger to close by year-end, pending final approvals
Outlook
Pulmatrix expects merger with Eos SENOLYTIX to close by end of 2026
Company says all clinical development is on hold while seeking to license or monetize assets
Pulmatrix anticipates cash position sufficient to fund operations through anticipated merger closing
Result Drivers
CLINICAL DEVELOPMENT ON HOLD - All clinical programs paused as company seeks to license or monetize assets
MERGER-RELATED COSTS - General and administrative expenses rose due to legal and professional services for proposed Eos SENOLYTIX merger
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | $0.34 |
Reuters Recommended Reads
Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall
Nov 16 - Moleculin Biotech Q3 net loss narrows as MIRACLE trial advances
Nov 16 - ALX Oncology Q3 net loss per share narrows
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)